Comparative effectiveness of statins in secondary prevention among the older people aged 75  years and over

Conclusion The results of this study support the preferential prescription of moderate-intensity rosuvastatin over moderate-intensity atorvastatin for the secondary prevention of ischemic cardiovascular and cerebrovascular events in older patients aged ≥ 75 years.
Source: International Journal of Clinical Pharmacy - Category: Drugs & Pharmacology Source Type: research